Pfizer monitors breast cancer drug in real patients
NCT ID NCT03445637
Summary
This study monitored the safety and effectiveness of the breast cancer drug IBRANCE in real-world medical settings in Korea. It followed over 550 women with advanced, hormone-sensitive breast cancer who were prescribed the drug as part of their normal care. The goal was to collect information on side effects and how well the drug worked outside of controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.